DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CRIZOTINIB
Clinical Trials for Crizotinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00939770 | Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Active, not recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2009-09-01 | RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. |
| NCT00939770 | Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Active, not recruiting | Children's Oncology Group | Phase 1/Phase 2 | 2009-09-01 | RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. |
| NCT01082380 | Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers | Completed | Pfizer | Phase 1 | 2010-03-01 | The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans. |
| NCT01121588 | An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) | Active, not recruiting | Pfizer | Phase 1 | 2011-03-01 | This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK. |
| NCT01125904 | A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers | Completed | Pfizer | Phase 1 | 2010-06-01 | An oral-liquid, pediatric form of crizotinib designed for use by pediatric patients is being tested for its' palatability in adults. |
| NCT01147055 | Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers | Completed | Pfizer | Phase 1 | 2010-07-01 | The purpose of this study is to estimate the effect of multiple doses of Rifampin on the single dose pharmacokinetics of Crizotinib in healthy volunteers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Crizotinib
Condition Name
Condition MeSH
Clinical Trial Locations for Crizotinib
Trials by Country
Clinical Trial Progress for Crizotinib
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Crizotinib
Sponsor Name
